Behind the Science: Anti-Inflammatory Effects of NLRP3 Inhibition with Ruvonoflast | JACC

Can targeting inflammation change the future of cardiovascular care?

In this episode of Behind the Science, Dr. Kausik K. Ray discusses groundbreaking findings from the JACC study examining ruvonoflast, an oral NLRP3 inhibitor, in individuals at elevated cardiovascular risk. Learn how this Phase 1b trial demonstrated reductions in key inflammatory biomarkers, including hsCRP and IL-6, and why these results could signal a new approach to cardiovascular disease prevention and treatment.

Read the full study: https://www.jacc.org/doi/10.1016/j.jacc.2026.05.014